How And Why Genzyme And Alnylam Expanded Their Alliance
Genzyme’s decision to deepen its alliance with Alnylam plays to the strategic needs of both parties and to their complementary strengths. The agreement also was helped by the companies’ physical proximity and by a high-level conversation between Maraganore and Viehbacher at a critical juncture.
You may also be interested in...
Under partnership with Intellia, Regeneron will use gene-editing technology to develop novel therapeutics against up to 10 targets, and will make a $50m equity investment in the biotech.
RNAi pioneer is getting closer to market with NDA filing in amyloidosis expected in 2017, but ample competition is coming along, albeit far behind.
Year-end earnings reports from the biotech crowd show movement in the biosimilar field, faith in RNAi, high value for rare disease approaches and strategies to defend and grow primary assets.